Taken together, these findings strongly suggest that the ABT-199/CS055 combination regimen might represent an effective therapy for the treatment of AML patients carrying high-risk FLT3-ITD, probably other poor-prognostic genetic alterations as well, although future studies are warranted to include more PDX models. The gene discussed is FLT3; the disease is acute myeloid leukemia.